The U.S. Federal Trade Commission (FTC) is seeking public comment on an application by Cardinal Health to sell former nuclear pharmacy assets to Patient Care Infusion (PCI).
The proposed transaction is required under a 2011 settlement with the FTC, which resolved charges that Cardinal's acquisition of three nuclear pharmacies from Biotech was anticompetitive.
The FTC's order also required Cardinal to sell nuclear pharmacies in Las Vegas, Albuquerque, and El Paso, TX. After Cardinal completed the acquisition, it closed its own nuclear pharmacies in each of the cities.
According to the FTC, these assets will be reconstituted through the sale to PCI, which has the ability to operate the new nuclear pharmacies in the cities in a competitive manner.
The FTC will accept comments until March 26.
